Abstract 11720: Efficacy and Safety of Apixaban versus Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review and Meta-Analysis
Abstract
Introduction: Apixaban and rivaroxaban are commonly used direct oral factor Xa inhibitors for acute venous thromboembolism (VTE), but uncertainty remains about their comparative effectiveness and bleeding risk across general and cancer-associated VTE populations. Research Question: We evaluated whether apixaban and rivaroxaban differ in efficacy and safety among adults treated for acute VTE, including subgroup analyses by cancer status. Methods: PubMed, Embase, and Cochrane CENTRAL were searched from inception to April 2026 for studies directly comparing apixaban with rivaroxaban in adults with acute VTE. Eligible studies reported recurrent VTE, recurrent deep vein thrombosis, recurrent pulmonary embolism, all-cause mortality, major bleeding, clinically relevant non-major bleeding (CRNMB), gastrointestinal bleeding, or intracranial bleeding. Subgroup analyses were performed for cancer-associated and non-cancer VTE populations where data were available. Random-effects meta-analyses were performed using risk ratios (RRs) with 95% confidence intervals (CIs). Heterogeneity was assessed using I 2 , and certainty of evidence was evaluated using GRADE. Results: Thirteen studies including 233,569 participants were analyzed; twelve were observational and one was a randomized clinical trial. Apixaban was not associated with a statistically significant difference in recurrent VTE compared with rivaroxaban in the primary analysis (RR, 0.82; 95% CI, 0.64-1.05; p=0.101; I 2 =54%). Recurrent deep vein thrombosis was lower with apixaban (RR, 0.88; 95% CI, 0.79-0.98; p=0.042; I 2 =0%), whereas recurrent pulmonary embolism and all-cause mortality did not differ significantly. Major bleeding was lower with apixaban (RR, 0.75; 95% CI, 0.57-0.99; p=0.0446; I 2 =57.8%), as were CRNMB (RR, 0.63; 95% CI, 0.53-0.75; p=0.002; I 2 =36.1%) and gastrointestinal bleeding (RR, 0.68; 95% CI, 0.62-0.75; p=0.001; I 2 =0%). Intracranial bleeding was not significantly different. In cancer-associated VTE, point estimates favored apixaban for recurrent VTE (RR, 0.62; 95% CI, 0.37-1.06) and major bleeding (RR, 0.88; 95% CI, 0.50-1.58). In non-cancer VTE, point estimates also favored apixaban for recurrent VTE (RR, 0.80; 95% CI, 0.48-1.34) and major bleeding (RR, 0.66; 95% CI, 0.36-1.22), although estimates were imprecise. Certainty of evidence was very low across outcomes. Conclusion: In adults with acute VTE, apixaban and rivaroxaban showed broadly comparable effectiveness. Apixaban was associated with lower risks of several bleeding outcomes, while subgroup findings in cancer-associated and non-cancer VTE were directionally consistent but imprecise.